Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement

FORT COLLINS, Colo.: FORT COLLINS, Colo., Aug. 12, 2021 /PRNewswire/ — Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced a collaboration agreement to fund research and laboratory facilities at the La Jolla Institute for Immunology (LJI), a not-for-profit academic institution and a world leader in immunology research. The agreement is directed to research that will support the development of potential new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune and chronic inflammatory diseases. The research will harness Cytocom’s proprietary drug discovery and development platform technology.
Click here to view original post